My ePortfolio Register   

Treatment options for elderly CLL patients

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 29.03.11
Views: 6647

Prof Peter Hillmen - St James's University Hospital, Leeds, UK

Prof Peter Hillmen speaks about the treatment options available for elderly chronic lymphocytic leukaemia (CLL). The current standard of care is chlorambucil but patients can achieve a deeper remission if treated with FCR (fludarabine, cyclophosphamide and rituximab). Patients may only receive FCR if they have reasonably good renal function and the FCR drug combination is highly immunosuppressive, making it unsuitable for patients with a high risk of infections.
Prof Hillmen discusses how clinicians should decide on the best treatment for each individual, outlines the need for large randomised trials of new drugs such as bendamustine and talks about the prospect of targeted therapies.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence